A detailed history of Tema Etfs LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Tema Etfs LLC holds 87,398 shares of EXEL stock, worth $3.64 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
87,398
Previous 59,259 47.48%
Holding current value
$3.64 Million
Previous $2.45 Billion 56.52%
% of portfolio
0.3%
Previous 0.2%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2025

Jan 16, 2026

BUY
$34.54 - $43.59 $971,921 - $1.23 Million
28,139 Added 47.48%
87,398 $3.83 Billion
Q3 2025

Oct 24, 2025

SELL
$36.22 - $46.25 $266,434 - $340,215
-7,356 Reduced 11.04%
59,259 $2.45 Billion
Q2 2025

Aug 13, 2025

SELL
$34.13 - $46.26 $166,588 - $225,795
-4,881 Reduced 6.83%
66,615 $2.94 Billion
Q1 2025

May 14, 2025

BUY
$32.38 - $39.16 $720,131 - $870,918
22,240 Added 45.15%
71,496 $2.64 Billion
Q4 2024

Feb 14, 2025

BUY
$25.39 - $36.46 $1.25 Million - $1.8 Million
49,256 New
49,256 $1.64 Billion

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $13.4B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Tema Etfs LLC Portfolio

Follow Tema Etfs LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tema Etfs LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tema Etfs LLC with notifications on news.